Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
$6.212M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
8.75%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
176.4M
Cash
2026 Q1
P/E
TTM
29.85
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $185.44 Million

About Translational Development Acquisition Corp

Translational Development Acquisition Corp (TDAC) is a blank check company incorporated on April 19, 2022 in the Cayman Islands as an exempted company, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, or similar business combination with one or more target businesses. TDAC does not generate operating revenue. It raises capital through an IPO and holds proceeds in a trust account managed by Continental Stock Transfer & Trust Company, pending completion of an initial business combination. The company has two officers as of the FY2025 10-K filing (filed March 30, 2026) and does not intend to employ full-time staff prior to closing a business combination. Its sponsor is TDAC Partners LLC, successor to Stone Capital Partners LLC. The company's leadership includes affiliates connected to biotech and investment platforms, suggesting an intended focus on life sciences or biopharmaceutical targets, though no target has been disclosed in the filing excerpts.

Revenue model
TDAC generates no operating revenue. IPO proceeds are held in a trust account and are not available for operations. The company has access to up to approximately $1,000,000 from IPO proceeds outside the trust account for working capital and expenses.
Products and services
Blank check shell company. Primary instruments include founder shares, private placement warrants, and trust account interests. No commercial products or services are offered.
Customers and end markets
No customers or commercial end markets. The company's intended end market, based on leadership affiliations disclosed in the FY2025 10-K, includes biotech and drug development sectors, but no acquisition target has been identified in the filing.
Value-chain role
Special purpose acquisition company (SPAC). Acts as a capital aggregation vehicle to identify, negotiate, and complete a business combination with a private operating company, providing that target with a path to public market listing.
Geographic exposure
Incorporated in the Cayman Islands. Listed on a U.S. exchange. No operating business with geographic revenue exposure as of the FY2025 10-K.

Source: SEC 10-K, filed 2026-03-30

Industry: Blank Checks

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support